Source: Virtual Congress 2021 – Biomarkers to phenotype asthma: prediction of exacerbations



Rating:

Share or cite this content

Citations should be made in the following way:
M. Gurnell (Cambridge, United Kingdom), L. Heaney (Belfast, United Kingdom), A. Menzies-Gow (London, United Kingdom), J. Corren (Los Angeles, United States of America), E. Bel (Amsterdam, Netherlands), J. Maspero (Buenos Aires, Argentina), T. Harrison (Nottingham , United Kingdom), D. Jackson (London, United Kingdom), D. Price (Singapore, Singapore), N. Lugogo (Ann Arbor, United States of America), A. Burden (Cambridge, United Kingdom), A. De Giorgio-Miller (Luton, United Kingdom), K. Padilla (Durham, United States of America), U. Martin (Gaithersburg, United States of America), E. Garcia Gil (Barcelona, Spain), J. Kreindler (Wilmington, United States of America). Late Breaking Abstract - Adrenal function improvement after oral corticosteroid reduction in benralizumab-treated severe eosinophilic asthma: PONENTE maintenance phase. 3723

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - The burden of intermittent oral corticosteroid use in asthma Source: Virtual Congress 2021 – Asthma treatment: clinical and translational science Year: 2021 Late Breaking Abstract - The impact of treatment with mepolizumab on airway remodeling in patients with severe eosinophilic asthma. Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Late Breaking Abstract: Tiotropium improves lung function in patients with severe uncontrolled asthma Source: Annual Congress 2010 - Treatment options for asthma Year: 2010 Late Breaking Abstract - Daily physical activity in patients with severe eosinophilic asthma and the effect of anti-IL5 therapy. Source: International Congress 2018 – New pharmacological strategies in airway diseases Year: 2018 Late Breaking Abstract - Clinical characteristics and lung function trends of severe eosinophilic asthma patients unresponsive to Mepolizumab Source: International Congress 2019 – Blood eosinophils and more in airway diseases Year: 2019 Late Breaking Abstract - Two-year cumulative oral corticosteroid exposure in severe eosinophilic asthma before and after anti-IL-5 therapy Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021 Late Breaking Abstract - Short-term and maintenance oral corticosteroid use for German patients with asthma Source: International Congress 2019 – Powerful cohort studies with/without lung function Year: 2019 Late Breaking Abstract - Real-life rapidity of dupilumab effects on symptom control, lung function and prednisone intake in patients with severe eosinophilic asthma and nasal polyposis Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Late Breaking Abstract - Efficacy of oral prednisolone in patients with stable severe eosinophilic asthma (SEA) treated with Mepolizumab Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Late Breaking Abstract - Mepolizumab reduces exacerbations in eosinophilic COPD Source: International Congress 2017 – Late-breaking studies in asthma and COPD Year: 2017 Late Breaking Abstract - Early response to benralizumab in Canadians with severe eosinophilic asthma Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Late Breaking Abstract: Persistent effect of bronchial thermoplasty (BT) in severe asthma at two years Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010 Late Breaking Abstract - Tiotropium/olodaterol improves pulmonary function in patients with treatment naive COPD Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Late Breaking Abstract - Daily physical activity in patients with severe asthma and the effect of anti-IL5 therapy. Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Late Breaking Abstract - Patients with severe eosinophilic asthma benefit from the treatment with Anti-IL-5 Reslizumab – a real life study from Austria Source: International Congress 2018 – Notable Studies in Asthma Year: 2018 Effect of a 10-day oral corticosteroid course on hemostasis and inflammation in patients with stable asthma Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Late Breaking Abstract: Inhaled pitrakinra, an IL-4/IL-13 antagonist, reduced exacerbations in patients with eosinophilic asthma Source: Annual Congress 2010 - Treatment options for asthma Year: 2010 Late Breaking Abstract - Benralizumab treatment strongly reduces blood basophils in patients with severe eosinophilic asthma Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019 Induced sputum in children With persistent asthma: The effect to inhaled corticosteroid treatment Source: Annual Congress 2013 –Monitoring asthma: genes, cells and molecules Year: 2013 Effect of oral corticosteroids on symptomatic reflux in severe allergic asthma: Is there a link? Source: International Congress 2014 – The assessment of comorbidities Year: 2014